Son rise at Sun: Decoding the architecture of Dilip Shanghvi’s global empire

Subscribe to enjoy similar stories.Mumbai: When Dilip Shanghvi walked into the press conference to announce Sun Pharmaceutical’s acquisition of Organon & Co.—an $11.75 billion deal that will effectively double the company’s revenue to $12.4 billion—he offered a rare admission.“I’m happy, excited, also a little bit anxious,” he told journalists, adding that the sheer size of the transaction reminded him of announcing the Ranbaxy Laboratories deal a decade ago.Back then, Sun was a fraction of its current size. This time, it is acquiring a company roughly equal in size, paying for it with cash and borrowed money rather than stock, and doing so at what Shanghvi described as “less than 25% of Sun’s own value.”At the surface, the Organon deal is a story about scale—a large Indian generics company buying an even larger portfolio of established branded drugs and biosimilars from a spun-off Merck subsidiary.

But strip away the financial architecture, and what emerges is something more layered: a calculated play away from the US generics business, a strategic entry into China and biosimilars that Sun has long coveted, and, perhaps most quietly, the de facto commissioning of an empire for the next generation.That next generation has a name: Aalok Shanghvi, 42, the founder’s son. He was elevated as the company’s chief operating officer (COO) in May 2025.

For over two decades, he has built the very international business that the Organon acquisition could now turbocharge.To understand why Shanghvi moved, you have to understand what stopped moving first: the US.In 2014, Sun Pharma was the archetype of a successful Indian pharmaceutical exporter. Its US business accounted for 60% of total revenue, built on a formidable machine of